Playing catch-up, Regeneron and Sanofi push ahead on pivotal PD-1 cancer studies
Regeneron $REGN is wasting no time in pushing ahead with what it hopes is their first pivotal study for the latest in what is becoming a long line of PD-1 checkpoint drugs. In its earnings release this morning the big biotech says that it is recruiting patients for a potential registration Phase II study on advanced cutaneous squamous cell carcinoma.
ISI analyst Mark Schoenebaum added in a note this morning that he’s keeping a close eye on their Phase II for non-small cell lung cancer, which also launches this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.